Quantcast
Home / News / Suit against maker of generic Reglan preempted

Suit against maker of generic Reglan preempted

A “failure to communicate” claim against the maker of generic Reglan was completely preempted by federal law regulating the pharmaceutical industry, the 11th U.S. Circuit Court of Appeals has ruled in affirming judgment.


Lawyers USA has ceased publication. If you have purchased a research pass or still have additional time on your current Digital Subscription, you may access locked stories by logging in:







Scroll To Top